Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05757492 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Coherus Oncology.
- Terminated
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT05757492 is a Phase 1 study that was terminated before completion, run by Coherus Oncology. The registered enrollment target is 22 participants.
The verdict
NCT05757492, a Phase 1 study, was terminated before completion, sponsored by Coherus Oncology.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
This phase 1 open-label study will evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of CHS-006 in combination with toripalimab in 2 phases. Phase 1 (Dose Optimization phase) will explore 2 different dose combinations in participants with advanced/metastatic solid tumors (except pancreatic) and Phase 2 (Indication-specific Expansion phase) will use one selected dose in specific tumor types (non-small cell lung cancer-non squamous \[NSCLC-NS\] and Hepatocellular carcinoma \[HCC\])
Interventions
- DRUG CHS-006 (anti-TIGIT)
- DRUG toripalimab (anti-PD-1)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2023-04-26 |
| Est. Completion | 2024-07-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05757492
The ClinicalTrials.gov registry entry for NCT05757492 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Coherus Oncology, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CHS-006 (anti-TIGIT) is the first listed.
NCT05757492 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05757492 about?
NCT05757492 is a clinical study titled "Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors". This phase 1 open-label study will evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of CHS-006 in combination with toripalimab in 2 phases. Phase 1 (Dose Optimization phase) will explore 2 different dose combinations in participants with advanced/metastatic solid tu...
What is the current status of trial NCT05757492?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2023-04-26. Estimated completion is 2024-07-31.
What interventions are being tested in trial NCT05757492?
The interventions under investigation include: CHS-006 (anti-TIGIT) (DRUG), toripalimab (anti-PD-1) (DRUG).
Who is sponsoring clinical trial NCT05757492?
This trial is sponsored by Coherus Oncology, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.